1. Home
  2. GH vs CUZ Comparison

GH vs CUZ Comparison

Compare GH & CUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GH
  • CUZ
  • Stock Information
  • Founded
  • GH 2011
  • CUZ 1958
  • Country
  • GH United States
  • CUZ United States
  • Employees
  • GH N/A
  • CUZ N/A
  • Industry
  • GH Medical Specialities
  • CUZ Real Estate Investment Trusts
  • Sector
  • GH Health Care
  • CUZ Real Estate
  • Exchange
  • GH Nasdaq
  • CUZ Nasdaq
  • Market Cap
  • GH 4.9B
  • CUZ 4.7B
  • IPO Year
  • GH 2018
  • CUZ N/A
  • Fundamental
  • Price
  • GH $61.40
  • CUZ $28.47
  • Analyst Decision
  • GH Strong Buy
  • CUZ Buy
  • Analyst Count
  • GH 16
  • CUZ 9
  • Target Price
  • GH $57.50
  • CUZ $32.11
  • AVG Volume (30 Days)
  • GH 3.4M
  • CUZ 1.6M
  • Earning Date
  • GH 07-30-2025
  • CUZ 10-23-2025
  • Dividend Yield
  • GH N/A
  • CUZ 4.63%
  • EPS Growth
  • GH N/A
  • CUZ N/A
  • EPS
  • GH N/A
  • CUZ 0.37
  • Revenue
  • GH $828,849,000.00
  • CUZ $917,942,000.00
  • Revenue This Year
  • GH $23.36
  • CUZ $13.63
  • Revenue Next Year
  • GH $21.43
  • CUZ $3.36
  • P/E Ratio
  • GH N/A
  • CUZ $76.66
  • Revenue Growth
  • GH 28.74
  • CUZ 11.98
  • 52 Week Low
  • GH $20.14
  • CUZ $24.07
  • 52 Week High
  • GH $62.81
  • CUZ $32.55
  • Technical
  • Relative Strength Index (RSI)
  • GH 72.00
  • CUZ 57.73
  • Support Level
  • GH $57.41
  • CUZ $27.46
  • Resistance Level
  • GH $59.92
  • CUZ $28.13
  • Average True Range (ATR)
  • GH 2.54
  • CUZ 0.56
  • MACD
  • GH 0.99
  • CUZ 0.18
  • Stochastic Oscillator
  • GH 92.69
  • CUZ 89.84

About GH Guardant Health Inc.

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

About CUZ Cousins Properties Incorporated

Cousins Properties Inc is a real estate investment trust principally involved in the ownership, management, and development of properties in the Southern United States. Cousins Properties' real estate portfolio mainly comprises offices and mixed-use developments that encompass both apartment and retail space. Offices make up the vast majority of the portfolio in terms of total square footage. The segments operates in following geographical areas: Atlanta, Austin, Charlotte, Dallas, Phoenix, Tampa, and other markets. The company derives nearly all of its revenue in the form of rental income from its properties, the majority of which comes from its office locations. A diverse set of tenants in the cities of Houston and Atlanta represent the company's key markets.

Share on Social Networks: